<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89050">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918852</url>
  </required_header>
  <id_info>
    <org_study_id>SALTO</org_study_id>
    <nct_id>NCT01918852</nct_id>
  </id_info>
  <brief_title>S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.</brief_title>
  <acronym>SALTO</acronym>
  <official_title>S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dutch Colorectal Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Pharma SAS</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dutch Colorectal Cancer Group</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a two-arm randomised phase III trial. Patients will be randomised  to receive
      capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the
      investigator. Patients will be followed 3-weekly at the outpatient clinic, toxicity will be
      assessed according to study protocol guidelines. Patients will be evaluated every 3 cycles
      for response. Upon disease progression patients will be treated according to the local
      investigators
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Capecitabine, an oral fluoropyrimidine, has shown a comparable efficacy but a better
      tolerability compared to bolus 5-FU/LV.  However, capecitabine has a higher incidence of
      hand-foot syndrome (HFS). HFS is characterized by erythema, dysesthesia and/or paresthesia
      of the palms of the hands or soles of feet. In advanced stage, desquamation, ulceration and
      blistering can occur.  Although HFS is not life threatening, it can cause significant
      discomfort and impairment of function, especially in elderly patients. This adverse event is
      becoming particularly relevant since many patients may require the administration of
      capecitabine over prolonged periods of time.

      S-1 (Teysuno®) is an oral fluoropyrimidine that has shown comparable efficacy to 5FU and
      capecitabine in gastrointestinal cancers but is associated with a much lower incidence of
      HFS. Studies on S-1 have mainly been performed in Asian patients,which population has known
      differences in tumour biology and toxicity compared to Western population. S-1 has shown
      comparable efficacy to other fluoropyrimidines as monotherapy or in combination chemotherapy
      schedules in several gastrointestinal tumors. However, given the lack of data from
      prospective studies on S-1 as monochemotherapy in metastatic colorectal cancer in Western
      patients, this study is designed to compare S-1 and capecitabine monotherapy in terms of
      safety, with particular interest in HFS, in metastatic colorectal cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of HFS in first line treatment</measure>
    <time_frame>HFS will be assessed every 3 weeks up to 6 months average.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the incidence of HFS in first line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3 HFS</measure>
    <time_frame>HFS will be assessed every 3 weeks, up to 6 months average</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of grade 3 hand-foot syndrome, according to CTC 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Every 9 weeks, for 6 months (average)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from randomisation until progression or death whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
    <time_frame>Every 3 weeks, for 6 months (average)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events graded accoording to the NCI CTCAE version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>From date of randomisation to death or last known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Response will be assessed every 9 weeks, up to 6 months average.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response acccording to RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Distant Metastases</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine 1250 mg/m2 for patients &lt; 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teysuno</intervention_name>
    <arm_group_label>S1</arm_group_label>
    <other_name>S1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_label>S1</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proof of colorectal cancer.

          -  Distant metastases (patients with only local recurrence are not eligible).

          -  Unidimensionally measurable disease (≥1 cm on spiral CT scan or ≥2 cm on chest X-ray;
             liver ultrasound is not allowed). Serum CEA may not be used as a parameter for
             disease evaluation.

          -  In case of previous radiotherapy, at least one measurable lesion should be located
             outside the irradiated field.

          -  Age ≥ 18 years

          -  Planned treatment with fluoropyrimidine monotherapy with or without bevacizumab.

          -  WHO performance status 0-2 (Karnofsky PS ≥70%)

          -  Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥1.5 x
             109/L, platelets ≥ 100 x 109/L), renal function (serum creatinine ≤ 1.5x ULN and
             creatinine clearance, Cockroft formula, ≥30 ml/min), liver function (serum bilirubin
             ≤ 2 x ULN, serum transaminases ≤ 3 x ULN without presence of liver metastases or ≤ 5x
             ULN with presence of liver metastases).

          -  Life expectancy &gt; 12 weeks.

          -  Negative pregnancy test in women with childbearing potential.

          -  Expected adequacy of follow-up.

          -  Institutional Review Board approval.

          -  Written informed consent.

        Exclusion Criteria:

          -  Prior adjuvant treatment for stage II/III colorectal cancer completed within 6 months
             prior to randomisation.

          -  Any prior adjuvant treatment after resection of distant metastases.

          -  Any previous systemic treatment for metastatic disease.

          -  History or clinical signs/symptoms of CNS metastases.

          -  History of a second malignancy &lt;5 years with the exception of adequately treated
             carcinoma of cervix or basal/squamous cell carcinoma of skin.

          -  Previous intolerance of capecitabine.

          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency or treatment within 4 weeks
             with DPD inhibitors, including sorivudine or its chemically related analogues such as
             brivudine.

          -  Planned radical resection of metastases after downsizing by systemic treatment.

          -  Significant cardiovascular disease &lt; 1 yr before randomisation (symptomatic
             congestive heart failure, myocardial ischemia or infarction, unstable angina
             pectoris, serious uncontrolled cardiac arrhythmia, arterial thrombosis,
             cerebrovascular event, pulmonary embolism).

          -  Any significant cardiovascular events during previous fluoropyrimidine therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelis JA Punt, Prof. MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Mol, MSc</last_name>
    <phone>+31 243616837</phone>
    <email>l.mol@iknl.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M P Hendriks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>C. Rodenburg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>C J Punt, Prof. MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>L. Simkens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>O C Leeksma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>H. Verheul, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annemieke Cats, MD PhD</last_name>
      <email>a.cats@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Marcel Verheij, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. Cats, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>P J Nieboer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Lievensberg</name>
      <address>
        <city>Bergen op Zoom</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>M Troost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>O Loosveld</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. ten Tije</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slingeland Ziekenhuis</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>E. Muller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catherina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>G J Creemers, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>M CJ Legdeur, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>M. Temizkan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>B. de Valk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M.B. Polee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>M Los</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waterland Ziekenhuis</name>
      <address>
        <city>Purmerend</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>J. A.C Brakenhof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>P. Hamberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vlietland Ziekenhuis</name>
      <address>
        <city>Schiedam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>J Ruit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orbis Medisch Centrum</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>F.L.G. Erdkamp, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tweesteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>S Goey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>M Koopman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>W MU van Grevenstein, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VieCuri Medisch Centrum</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Y van de Wouw, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>A Bochove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hand-foot syndrome</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Fluoropyrimidine</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Teysuno</keyword>
  <keyword>S1</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
